CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 356 enrolled
Drug / intervention
GORE® PROPATEN® Vascular Graft +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05124184
NCT05124184N/ACompleted
CompareCT.gov

Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access

W.L.Gore & Associates·observational·Posted Nov 17, 2021·Updated May 9, 2025

In Brief

An observational study evaluating GORE® PROPATEN® Vascular Graft and GORE-TEX® Vascular Grafts for PAD - Peripheral Arterial Disease and 2 related conditions. Completed, enrolled 356 participants across 8 sites in 3 countries.

Detailed Summary

This multicenter, single-arm retrospective registry (chart review) is being conducted to confirm the clinical performance and safety of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft throughout the device functional lifetime for each indication area.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPAD - Peripheral Arterial Disease, AAA - Abdominal Aortic Aneurysm, End-Stage Renal Disease
CountriesFrance, Italy, Spain
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 17, 2021
Enrollment StartJan 24, 2022
Primary CompletionJul 22, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.6 years ago

Interventions

GORE® PROPATEN® Vascular Graftdevice

Patients that have had treatment with GORE® PROPATEN® Vascular Graft

GORE-TEX® Vascular Graftsdevice

Patients that have had treatment with GORE-TEX® Vascular Grafts